# Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

> **NCT06511908** · PHASE2 · RECRUITING · sponsor: **National Institute of Mental Health (NIMH)** · enrollment: 50 (estimated)

## Conditions studied

- Suicide
- Depressive Disorder, Treatment-Resistant
- Ketamine
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Agents
- Excitatory Amino Acid Agents
- Physiological Effects of Drugs
- Depressive Disorder, Major
- Depressive Disorder
- Depression
- Mental Disorders
- Mood Disorders
- Behavioral Symptoms

## Interventions

- **DRUG:** (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06511908
- **Lead sponsor:** National Institute of Mental Health (NIMH)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06511908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06511908, "Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06511908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*